JMP Securities Reiterates Market Outperform on Jasper Therapeutics, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating for Jasper Therapeutics (NASDAQ:JSPR) and maintained a $70 price target.
October 15, 2024 | 4:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating for Jasper Therapeutics, maintaining a $70 price target, indicating confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $70 by JMP Securities suggests a positive outlook for Jasper Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100